Loading clinical trials...

The Effect of Tart Cherry (Prunus Cerasus) Concentrate on Physiological and Cognitive Function | Clinical Trials | Clareo Health

COMPLETEDNA

The Effect of Tart Cherry (Prunus Cerasus) Concentrate on Physiological and Cognitive Function

The Effect of Tart Cherry (Prunus Cerasus) Concentrate on Cardiometabolic Risk Factors, Exercise Capacity and Cognitive Function

NCT04021342•Northumbria University

View on ClinicalTrials.gov

Summary

A randomized, double blind, counterbalanced, placebo controlled independent groups design to determine the effects of 3 month supplementation with tart cherry concentrate on indices of cardiometabolic health, exercise capacity and cognitive function. Following screening and recruitment, participants are familiarised with the testing equipment and procedures after which they will be randomly assigned to receive either Montmorency tart cherry concentrate (MC) or an isocaloric placebo (PLA), stratified by gender. The study is comprised of two experimental visits and outcome variables are assessed at baseline (before supplementation) and at 3 months (follow up; after supplementation).

Eligibility

Age

40 - 60 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy individuals between the ages of 40-60 years
•consume on average ≤5 servings of fruits and vegetables per day
•additionally have ≥1 risk factor for type 2 diabetes

Exclusion Criteria

•not regularly taking medication (or stabilised ≥ 3 months, with no adverse symptoms) or antioxidant supplements
•history of cardiometabolic, gastointestinal disease or malabsorption syndromes
•stage 2 hypertension (SBP \>159 mm Hg or DBP \>99 mm Hg)
•individuals who report changes in dietary or physical activity patterns within 3 months
•vegetarians, vegans or known eating disorders
•alcohol intake of more than 21 units per week
•BMI ≥40 kg/m2
•are pregnant or planning to become pregnant during the study, lactating, or initiating or changing a hormone replacement therapy regimen within 3 months of the start of the study

Locations (1)

Northumbria University

Newcastle upon Tyne, United Kingdom

Key Dates

Start Date

October 12, 2018

Primary Completion Date

November 29, 2019

Completion Date

February 29, 2020

Last Updated

April 8, 2021

Enrollment

ACTUAL participants

Conditions

Cardiometabolic Risk FactorsCognitive FunctionExercise Capacity

Interventions

Montmorency tart cherry concentrate

DIETARY_SUPPLEMENT

Placebo

DIETARY_SUPPLEMENT

Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity

NCT06638671

Exercise CapacityMetformin

View study

RECRUITINGNA

Multi-level Approach of Brain Activity Using Intracranial Electrodes in Epileptic Patients

NCT04653012

Focal EpilepsyElectrodes, Implanted+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 8, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effect of Tart Cherry (Prunus Cerasus) Concentrate on Physiological and Cognitive Function

Inclusion Criteria

Exclusion Criteria

Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity

Multi-level Approach of Brain Activity Using Intracranial Electrodes in Epileptic Patients

Effects of Milk-based Drinks on Gut Microbiome, Sleep and Cardiometabolic Markers

Associations Between Dietary Intake and Cardiometabolic and Gut Microbiota Outcomes

Brain Health in Breast Cancer Survivors

Exercise Capacity, Muscle Oxygenation, and Physical Activity Between Patients With Interstitial Lung Disease